Name: Bright Minds Biosciences Inc. (DRUG) Cash Flow Statement
Creator: FinSpry

Bright Minds Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions CAD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Bright Minds Biosciences Inc. (DRUG) - Annual data in millions CAD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Operating Activities
Net Income	-12.23	-2.80	-7.37	-14.96	-8.65
Depreciation & Amortization	0.08	0.07	0.07	0.01	0.00
Stock Based Compensation	3.18	0.84	1.15	0.88	0.88
Change in Working Capital	0.55	0.04	-0.94	0.72	0.31
Change in Accounts Receivable	-0.36	0.00	0.00	0.00	0.00
Change in Accounts Payable	0.00	0.24	-1.20	0.77	0.51
Change in Other Working Capital	0.92	0.01	0.26	0.03	-0.20
Other Operating Activities	-0.28	0.01	0.07	0.03	0.14
Net Cash from Operating Activities	-8.69	-1.85	-7.02	-13.59	-7.32
Investing Activities
Net Cash from Investing Activities	0.00	0.00	0.00	0.00	0.00
Financing Activities
Debt Repayment	-0.10	-0.09	-0.09	-0.01	0.00
Common Stock Issued	85.67	0.90	1.47	4.03	27.84
Other Financing Activities	0.00	0.00	0.80	-0.80	-1.79
Net Cash from Financing Activities	85.57	0.81	2.19	5.20	26.06
Summary
Effect of Forex Changes on Cash	0.31	0.01	-0.05	0.26	0.00
Net Change in Cash	77.19	-1.04	-4.88	-8.39	18.96
Cash at Beginning of Period	5.72	6.75	11.63	19.76	0.00
Cash at End of Period	82.91	5.72	6.75	11.63	0.00
Free Cash Flow	-8.69	-1.85	-7.02	-13.59	0.00